The US Food and Drug Administration (FDA) has extended the clinical hold on Ortho Regenerative Technologies’ investigational new drug (IND) application to commence a Phase I/II clinical trial of ORTHO-R in rotator cuff tear repair.

A Chitosan-Platelet-Rich Plasma (PRP) hybrid drug/biologic implant combination product, ORTHO-R is formulated and made to enhance the healing rates of occupational and sports-related damages to tendons, meniscus and ligaments.

It is used as an adjunct to standard of care surgical procedures in rotator cuff tear repair.

During a routine surgery, ORTHO-R can be directly delivered into the injury site by a surgeon without increasing operative procedure time and additional intervention.

In the initial clinical hold letter issued in June 2021, the FDA sought additional Chemistry, Manufacturing, and Control (CMC) related data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA has now accepted the three most complex supplemental data on characterisation at point of care and CMC, submitted by the company in response to the initial letter.

But the agency has sought additional clarifications on two advanced approaches of impurity characterisation, including further planned testing method.

Ortho Regenerative Technologies president and CEO Claude LeDuc said: “We are pleased to see that the FDA has accepted the recently submitted sterility and endotoxin level testing on the autologous PRP/ORTHO-R preparation workflow, as well as the identification of the drug substance following reconstitution in water, rather than in PRP.

“We are already working with our CMC experts, on the new CMC clarifications requested by the FDA. They relate to advanced methods of characterisation used in the CMC processes, to assess impurities.”

Clinical aspects to initiate the trial are all good, the company added.

The prospective, randomised, controlled and blinded Phase I/II trial intends to assess the safety and efficacy of ORTHO-R along with standard of care (SoC) surgery compared with SoC alone in rotator cuff tear repair.

It will enrol a total of 78 subjects at ten clinical centres in the US in the coming months.